Global Glioblastoma Multiforme Treatment (GBM) Market to Reach $4.3 Billion by 2030
The global market for Glioblastoma Multiforme Treatment (GBM) estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$4.3 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2022-2030. Radiation Therapy, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$1.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Surgery segment is readjusted to a revised 8.8% CAGR for the next 8-year period.
The U.S. Market is Estimated at $713.5 Million, While China is Forecast to Grow at 7% CAGR
The Glioblastoma Multiforme Treatment (GBM) market in the U.S. is estimated at US$713.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$741.3 Million by the year 2030 trailing a CAGR of 7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.5% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.Select Competitors (Total 33 Featured) -
- Amneal Pharmaceuticals, Inc.
- CARsgen Therapeutics
- Epitopoietic Research Corporation (ERC.SA.)
- F. Hoffmann-La Roche AG
- GBM Communications
- GBM Digital Technologies
- ImmunoCellular Therapeutics Ltd.
- Ivy Foundation
- Sapience Therapeutics
- SonALAsense
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Glioblastoma Multiforme Treatment (GBM) - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Glioblastoma Multiforme Treatment (GBM) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Tumor Treating Field (TTF) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Tumor Treating Field (TTF) Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Tumor Treating Field (TTF) Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 26: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 27: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 29: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 30: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: World 16-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 32: USA Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: USA 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 35: USA Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: USA Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: USA 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- CANADA
- Table 38: Canada Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Canada 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 41: Canada Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Canada Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Canada 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- JAPAN
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 44: Japan Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Japan 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 47: Japan Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: Japan Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Japan 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- CHINA
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 50: China Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: China 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 53: China Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: China Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: China 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- EUROPE
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 56: Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 62: Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- FRANCE
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 65: France Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: France 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 68: France Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: France Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: France 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- GERMANY
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 71: Germany Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Germany 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 74: Germany Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Germany Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Germany 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- ITALY
- Table 77: Italy Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Italy 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 80: Italy Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Italy Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: Italy 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 83: UK Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: UK 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 86: UK Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: UK Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: UK 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 89: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Rest of Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Glioblastoma Multiforme Treatment (GBM) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Asia-Pacific Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Asia-Pacific 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 101: Rest of World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Treatment - Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Rest of World 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Treatment - Percentage Breakdown of Value Sales for Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Immunotherapy for the Years 2014, 2023 & 2030
- Table 104: Rest of World Recent Past, Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Rest of World Historic Review for Glioblastoma Multiforme Treatment (GBM) by End-Use - Hospitals, Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Rest of World 16-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Ambulatory Surgery Centers for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amneal Pharmaceuticals, Inc.
- CARsgen Therapeutics
- Epitopoietic Research Corporation (ERC.SA.)
- F. Hoffmann-La Roche AG
- GBM Communications
- GBM Digital Technologies
- ImmunoCellular Therapeutics Ltd.
- Ivy Foundation
- Sapience Therapeutics
- SonALAsense
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 192 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2.4 Billion |
| Forecasted Market Value ( USD | $ 4.3 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
